This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Sumitomo Dainippon Pharma Oncology, Inc., Sumitomo Pharma Oncology, Inc.. Active years: 2021-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 11 
1 out of 11 Years Active: 2021-2022
Title: Akihito Nonoyama: Innovator in Oncology
Introduction
Akihito Nonoyama is a prominent inventor based in Hyogo, Japan. He has made significant contributions to the field of oncology through his innovative research and development of therapeutic compounds. With a total of 2 patents, Nonoyama's work focuses on advancing cancer treatment options.
Latest Patents
His latest patents include AXL kinase inhibitors and their use, specifically tartrate salts of the compound of structure (I). These patents detail crystalline forms and therapeutic applications for treating solid tumors, including advanced solid tumors and hematopoietic cancers. Additionally, the patents provide methods for synthesizing the tartrate salts and the crystalline forms thereof.
Career Highlights
Throughout his career, Akihito Nonoyama has worked with notable companies such as Sumitomo Dainippon Pharma Oncology, Inc. and Sumitomo Pharma Oncology, Inc. His expertise in oncology has positioned him as a key figure in the development of innovative cancer therapies.
Collaborations
Nonoyama has collaborated with esteemed colleagues, including Adam Siddiqui-Jain and Paul Flynn, to further enhance his research and development efforts in the field of oncology.
Conclusion
Akihito Nonoyama's contributions to cancer treatment through his patents and collaborations highlight his dedication to improving patient outcomes. His innovative work continues to influence the field of oncology significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile